1.8% for non-GLP-1 RA over 36 months and had a hazard ratio (HR) of 4.28 (95% CI, 1.62-11.29
While such strategies may offer some cost relief or expanded access, they also introduce important compliance, data visibility, and employee considerations
Looking for peptides injections near me or a reliable source for peptide near me options
Regarding medication breakdown, the study reported that 95.4% of patients were on compounded semaglutide while only 4.6% used branded semaglutide - a split the authors note was largely driven by supply shortages of branded semaglutide during the study period
Beyond diet, lifestyle factors also matter
It is important to remember that individual responses to medication can vary, and what works for one person may not work for another